Table of Contents 1 Market Overview 1.1 CINV Existing and Pipeline Drugs Introduction 1.2 Market Analysis by Type 1.2.1 Aloxi (palonosetron) 1.2.2 Zofran Generic (ondansetron) 1.2.3 Kytril Generic (granisetron) 1.2.4 Emend (aprepitant) 1.2.5 Akynzeo (netupitant-palonosetron) 1.2.6 SUSTOL (extended release granisetron injection) 1.2.7 Rolapitant 1.3 Market Analysis by Applications 1.3.1 Hospitals 1.3.2 Specialty Clinics 1.3.3 Diagnostic Centers Therapeutics 1.3.4 Hospital Pharmacies 1.3.5 Drugstores 1.4 Market Analysis by Regions 1.4.1 North America (United States, Canada and Mexico) 1.4.1.1 United States Market States and Outlook (2013-2023) 1.4.1.2 Canada Market States and Outlook (2013-2023) 1.4.1.3 Mexico Market States and Outlook (2013-2023) 1.4.2 Europe (Germany, France, UK, Russia and Italy) 1.4.2.1 Germany Market States and Outlook (2013-2023) 1.4.2.2 France Market States and Outlook (2013-2023) 1.4.2.3 UK Market States and Outlook (2013-2023) 1.4.2.4 Russia Market States and Outlook (2013-2023) 1.4.2.5 Italy Market States and Outlook (2013-2023) 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 1.4.3.1 China Market States and Outlook (2013-2023) 1.4.3.2 Japan Market States and Outlook (2013-2023) 1.4.3.3 Korea Market States and Outlook (2013-2023) 1.4.3.4 India Market States and Outlook (2013-2023) 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023) 1.4.4 South America, Middle East and Africa 1.4.4.1 Brazil Market States and Outlook (2013-2023) 1.4.4.2 Egypt Market States and Outlook (2013-2023) 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023) 1.4.4.4 South Africa Market States and Outlook (2013-2023) 1.4.4.5 Nigeria Market States and Outlook (2013-2023) 1.5 Market Dynamics 1.5.1 Market Opportunities 1.5.2 Market Risk 1.5.3 Market Driving Force 2 Manufacturers Profiles 2.1 GlaxoSmithKline 2.1.1 Business Overview 2.1.2 CINV Existing and Pipeline Drugs Type and Applications 2.1.2.1 Product A 2.1.2.2 Product B 2.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.2 Helsinn 2.2.1 Business Overview 2.2.2 CINV Existing and Pipeline Drugs Type and Applications 2.2.2.1 Product A 2.2.2.2 Product B 2.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.3 Heron Therapeutics 2.3.1 Business Overview 2.3.2 CINV Existing and Pipeline Drugs Type and Applications 2.3.2.1 Product A 2.3.2.2 Product B 2.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.4 Merck 2.4.1 Business Overview 2.4.2 CINV Existing and Pipeline Drugs Type and Applications 2.4.2.1 Product A 2.4.2.2 Product B 2.4.3 Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 2.5 Tesaro 2.5.1 Business Overview 2.5.2 CINV Existing and Pipeline Drugs Type and Applications 2.5.2.1 Product A 2.5.2.2 Product B 2.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) 3 Global CINV Existing and Pipeline Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017) 3.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Manufacturer (2016-2017) 3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Manufacturer (2016-2017) 3.3 Market Concentration Rate 3.3.1 Top 3 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2017 3.3.2 Top 6 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2017 3.4 Market Competition Trend 4 Global CINV Existing and Pipeline Drugs Market Analysis by Regions 4.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Regions 4.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Regions (2013-2018) 4.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Regions (2013-2018) 4.2 North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 4.3 Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 4.4 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 4.5 South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 4.6 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 5 North America CINV Existing and Pipeline Drugs by Countries 5.1 North America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries 5.1.1 North America CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018) 5.1.2 North America CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018) 5.2 United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 5.3 Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 5.4 Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 6 Europe CINV Existing and Pipeline Drugs by Countries 6.1 Europe CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries 6.1.1 Europe CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018) 6.1.2 Europe CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018) 6.2 Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 6.3 UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 6.4 France CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 6.5 Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 6.6 Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 7 Asia-Pacific CINV Existing and Pipeline Drugs by Countries 7.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries 7.1.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018) 7.1.2 Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018) 7.2 China CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 7.3 Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 7.4 Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 7.5 India CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 7.6 Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 8 South America CINV Existing and Pipeline Drugs by Countries 8.1 South America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries 8.1.1 South America CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018) 8.1.2 South America CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018) 8.2 Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 8.3 Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 8.4 Colombia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 9 Middle East and Africa CINV Existing and Pipeline Drugs by Countries 9.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries 9.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018) 9.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018) 9.2 Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 9.3 UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 9.4 Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 9.5 Nigeria CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 9.6 South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) 10 Global CINV Existing and Pipeline Drugs Market Segment by Type 10.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Type (2013-2018) 10.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Type (2013-2018) 10.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2013-2018) 10.2 Aloxi (palonosetron) Sales Growth and Price 10.2.1 Global Aloxi (palonosetron) Sales Growth (2013-2018) 10.2.2 Global Aloxi (palonosetron) Price (2013-2018) 10.3 Zofran Generic (ondansetron) Sales Growth and Price 10.3.1 Global Zofran Generic (ondansetron) Sales Growth (2013-2018) 10.3.2 Global Zofran Generic (ondansetron) Price (2013-2018) 10.4 Kytril Generic (granisetron) Sales Growth and Price 10.4.1 Global Kytril Generic (granisetron) Sales Growth (2013-2018) 10.4.2 Global Kytril Generic (granisetron) Price (2013-2018) 10.5 Emend (aprepitant) Sales Growth and Price 10.5.1 Global Emend (aprepitant) Sales Growth (2013-2018) 10.5.2 Global Emend (aprepitant) Price (2013-2018) 10.6 Akynzeo (netupitant-palonosetron) Sales Growth and Price 10.6.1 Global Akynzeo (netupitant-palonosetron) Sales Growth (2013-2018) 10.6.2 Global Akynzeo (netupitant-palonosetron) Price (2013-2018) 10.7 SUSTOL (extended release granisetron injection) Sales Growth and Price 10.7.1 Global SUSTOL (extended release granisetron injection) Sales Growth (2013-2018) 10.7.2 Global SUSTOL (extended release granisetron injection) Price (2013-2018) 10.8 Rolapitant Sales Growth and Price 10.8.1 Global Rolapitant Sales Growth (2013-2018) 10.8.2 Global Rolapitant Price (2013-2018) 11 Global CINV Existing and Pipeline Drugs Market Segment by Application 11.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2013-2018) 11.2 Hospitals Sales Growth (2013-2018) 11.3 Specialty Clinics Sales Growth (2013-2018) 11.4 Diagnostic Centers Therapeutics Sales Growth (2013-2018) 11.5 Hospital Pharmacies Sales Growth (2013-2018) 11.6 Drugstores Sales Growth (2013-2018) 12 CINV Existing and Pipeline Drugs Market Forecast (2018-2023) 12.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2023) 12.2 CINV Existing and Pipeline Drugs Market Forecast by Regions (2018-2023) 12.2.1 North America CINV Existing and Pipeline Drugs Market Forecast (2018-2023) 12.2.2 Europe CINV Existing and Pipeline Drugs Market Forecast (2018-2023) 12.2.3 Asia-Pacific CINV Existing and Pipeline Drugs Market Forecast (2018-2023) 12.2.4 South America CINV Existing and Pipeline Drugs Market Forecast (2018-2023) 12.2.5 Middle East and Africa CINV Existing and Pipeline Drugs Market Forecast (2018-2023) 12.3 CINV Existing and Pipeline Drugs Market Forecast by Type (2018-2023) 12.3.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2018-2023) 12.3.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2018-2023) 12.4 CINV Existing and Pipeline Drugs Market Forecast by Application (2018-2023) 12.4.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2018-2023) 12.4.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2018-2023) 13 Sales Channel, Distributors, Traders and Dealers 13.1 Sales Channel 13.1.1 Direct Marketing 13.1.2 Indirect Marketing 13.1.3 Marketing Channel Future Trend 13.2 Distributors, Traders and Dealers 14 Research Findings and Conclusion 15 Appendix 15.1 Methodology 15.2 Data Source

List of Tables and Figures Figure CINV Existing and Pipeline Drugs Picture Table Product Specifications of CINV Existing and Pipeline Drugs Figure Global Sales Market Share of CINV Existing and Pipeline Drugs by Types in 2017 Table CINV Existing and Pipeline Drugs Types for Major Manufacturers Figure Aloxi (palonosetron) Picture Figure Zofran Generic (ondansetron) Picture Figure Kytril Generic (granisetron) Picture Figure Emend (aprepitant) Picture Figure Akynzeo (netupitant-palonosetron) Picture Figure SUSTOL (extended release granisetron injection) Picture Figure Rolapitant Picture Figure CINV Existing and Pipeline Drugs Sales Market Share by Applications in 2017 Figure Hospitals Picture Figure Specialty Clinics Picture Figure Diagnostic Centers Therapeutics Picture Figure Hospital Pharmacies Picture Figure Drugstores Picture Figure United States CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Canada CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Mexico CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Germany CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure France CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure UK CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Russia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Italy CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure China CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Japan CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Korea CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure India CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Southeast Asia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Brazil CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Egypt CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Saudi Arabia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure South Africa CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Figure Nigeria CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023) Table GlaxoSmithKline Basic Information, Manufacturing Base and Competitors Table GlaxoSmithKline CINV Existing and Pipeline Drugs Type and Applications Table GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) Table Helsinn Basic Information, Manufacturing Base and Competitors Table Helsinn CINV Existing and Pipeline Drugs Type and Applications Table Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) Table Heron Therapeutics Basic Information, Manufacturing Base and Competitors Table Heron Therapeutics CINV Existing and Pipeline Drugs Type and Applications Table Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) Table Merck Basic Information, Manufacturing Base and Competitors Table Merck CINV Existing and Pipeline Drugs Type and Applications Table Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) Table Tesaro Basic Information, Manufacturing Base and Competitors Table Tesaro CINV Existing and Pipeline Drugs Type and Applications Table Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017) Table Global CINV Existing and Pipeline Drugs Sales by Manufacturer (2016-2017) Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2016 Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2017 Table Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2016-2017) Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2016 Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2017 Figure Top 3 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2017 Figure Top 6 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2017 Figure Global CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Global CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018) Table Global CINV Existing and Pipeline Drugs Sales by Regions (2013-2018) Table Global CINV Existing and Pipeline Drugs Sales Market Share by Regions (2013-2018) Table Global CINV Existing and Pipeline Drugs Revenue by Regions (2013-2018) Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2013 Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2017 Figure North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure North America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018) Table North America CINV Existing and Pipeline Drugs Sales by Countries (2013-2018) Table North America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018) Figure North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2013 Figure North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017 Table North America CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018) Table North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018) Figure North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2013 Figure North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017 Figure United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Europe CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018) Table Europe CINV Existing and Pipeline Drugs Sales by Countries (2013-2018) Table Europe CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018) Table Europe CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018) Figure Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2016 Figure Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017 Figure Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure France CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018) Table Asia-Pacific CINV Existing and Pipeline Drugs Sales by Countries (2013-2018) Table Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018) Figure Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries 2017 Table Asia-Pacific CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018) Figure Asia-Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Countries 2017 Figure China CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure India CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure South America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018) Table South America CINV Existing and Pipeline Drugs Sales by Countries (2013-2018) Table South America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018) Figure South America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017 Table South America CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018) Table South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018) Figure South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017 Figure Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Colombia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018) Table Middle East and Africa CINV Existing and Pipeline Drugs Sales by Countries (2013-2018) Table Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018) Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017 Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018) Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018) Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2013 Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017 Figure Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure Nigeria CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Figure South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018) Table Global CINV Existing and Pipeline Drugs Sales by Type (2013-2018) Table Global CINV Existing and Pipeline Drugs Sales Share by Type (2013-2018) Table Global CINV Existing and Pipeline Drugs Revenue by Type (2013-2018) Table Global CINV Existing and Pipeline Drugs Revenue Share by Type (2013-2018) Figure Global Aloxi (palonosetron) Sales Growth (2013-2018) Figure Global Aloxi (palonosetron) Price (2013-2018) Figure Global Zofran Generic (ondansetron) Sales Growth (2013-2018) Figure Global Zofran Generic (ondansetron) Price (2013-2018) Figure Global Kytril Generic (granisetron) Sales Growth (2013-2018) Figure Global Kytril Generic (granisetron) Price (2013-2018) Figure Global Emend (aprepitant) Sales Growth (2013-2018) Figure Global Emend (aprepitant) Price (2013-2018) Figure Global Akynzeo (netupitant-palonosetron) Sales Growth (2013-2018) Figure Global Akynzeo (netupitant-palonosetron) Price (2013-2018) Figure Global SUSTOL (extended release granisetron injection) Sales Growth (2013-2018) Figure Global SUSTOL (extended release granisetron injection) Price (2013-2018) Figure Global Rolapitant Sales Growth (2013-2018) Figure Global Rolapitant Price (2013-2018) Table Global CINV Existing and Pipeline Drugs Sales by Application (2013-2018) Table Global CINV Existing and Pipeline Drugs Sales Share by Application (2013-2018) Figure Global Specialty Clinics Sales Growth (2013-2018) Figure Global Diagnostic Centers Therapeutics Sales Growth (2013-2018) Figure Global Hospital Pharmacies Sales Growth (2013-2018) Figure Global Drugstores Sales Growth (2013-2018) Figure Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2023) Table Global CINV Existing and Pipeline Drugs Sales Forecast by Regions (2018-2023) Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Regions (2018-2023) Figure North America Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023) Figure Europe Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023) Figure Asia-Pacific Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023) Figure South America Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023) Figure Middle East and Africa Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023) Table Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2018-2023) Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2018-2023) Table Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2018-2023) Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2018-2023) Table Distributors/Traders/ Dealers List

GlaxoSmithKline Helsinn Heron Therapeutics Merck Tesaro